hafnium has been researched along with Soft Tissue Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nussbaum, DP | 1 |
| Agoston, P; Anghel, R; Austen, L; Bonvalot, S; Borkowska, A; Bovée, JVMG; Carrère, S; Co, A; de Baère, T; Dema, S; Ducassou, A; Gebhart, M; Gronchi, A; Helfre, S; Herraez, AC; Hohenberger, P; Hong, A; Kacso, G; Kantor, G; Lapeire, L; Lazar, AJ; Le Cesne, A; Le Péchoux, C; Li, RK; Loong, HH; Mangel, L; Mervoyer, A; Montero, A; Moreno, V; Moureau-Zabotto, L; Papai, Z; Rastrelli, M; Rutkowski, PL; Saada-Bouzid, E; Servois, V; Sunyach, MP; Sy-Ortin, T; Terrier, P; Thariat, J; Tiangco, B; Vergés, R; Wardelmann, E | 1 |
1 trial(s) available for hafnium and Soft Tissue Neoplasms
| Article | Year |
|---|---|
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Female; Hafnium; Humans; Male; Middle Aged; Nanoparticles; Oxides; Radiation-Sensitizing Agents; Radiotherapy; Sarcoma; Soft Tissue Neoplasms; Young Adult | 2019 |
1 other study(ies) available for hafnium and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Nanoparticle augmentation of radiotherapy in sarcoma.
Topics: Hafnium; Humans; Nanoparticles; Oxides; Sarcoma; Soft Tissue Neoplasms | 2019 |